A pre-market lift for shares of Xenoport Inc. (NASDAQ:XNPT) quickly deflated Tuesday following release of preliminary top-line results from the phase II trial of XP23829 in moderate to severe chronic plaque-type psoriasis. Shares closed at $4.84 for a loss of $1.89, or 28.1 percent.